Covidien Remains at Neutral – Analyst Blog

By | December 28, 2012
0 Comment

We have reiterated our Neutral recommendation on leading health care products maker, Covidien plc. ( COV ), with a target price of $60.

More here:
Covidien Remains at Neutral – Analyst Blog

Related posts:

  1. VeriSign Remains at Neutral Rec – Analyst Blog
  2. hhgregg Remains Neutral – Analyst Blog
  3. Medtronic Remains Neutral – Analyst Blog
  4. ERJ Remains in Neutral Zone – Analyst Blog